Nasdaq: BLSM · Listed Aug 7, 2026
BlossomHill Therapeutics Inc.. IPO
IPO price
$16.00
BlossomHill Therapeutics Inc.. (BLSM) priced its IPO at $16.00 a share and has traded on Nasdaq since Aug 7, 2026.
BLSM today$14.59-8.81%since IPO15-min delayed · as of 4:40:11 PM EST on Nov 18, 2026
See the BLSM quoteFirst trading day · Aug 7, 2026
- IPO price
- $16.00
- inside the range of $15 to $17
- First trade
- $15.75
- -1.56% from the IPO price
- First-day last trade
- $16.00
- +0.00% from the IPO price, regular session
- Raise
- $150M
- before the underwriters' option
These numbers are from the first trading day, Aug 7, 2026.
How BLSM did against the market
BLSM against the market, from its first trade at 12:30 ET to the last trade of the session.
- BLSM from its first trade
- +1.59%
- Against the market (QQQ)
- +1.2 pts
BLSM rose 1.6% from its first trade to the last trade of the session. That is 1.2 points better than the market.
Same-day moves do not show that BLSM caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
BLSM against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
BLSM against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| BlossomHill Therapeutics Inc.. '26 | $150M | -1.56% | +0.00% | +2.12% | +60.69% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The BlossomHill Therapeutics Inc.. IPO offers 9.38M shares to raise $150M, before any underwriters' option.
- Expected price range
- $15 to $17
- IPO price
- $16.00
- Shares offered
- 9.38M
- Money raised
- $150M
- Listing date
- Aug 7, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- BlossomHill Therapeutics Inc..$150M
Where BLSM ranks
BlossomHill Therapeutics Inc..'s market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- BLSM$463.74M
Filings and the company
What BlossomHill Therapeutics Inc.. has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that BlossomHill Therapeutics Inc.. discloses to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, BlossomHill Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.
- Quarterly earningsSep 18, 2026
On September 18, 2026, BlossomHill Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2026.
- Clinical trial resultsSep 15, 2026
On September 15, 2026, BlossomHill Therapeutics, Inc. issued a press release announcing updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S.
- Public offeringAug 10, 2026
On August 10, 2026, the Company completed its IPO of an aggregate of 9,375,000 shares of common stock at a price to the public of $16.00 per share. The aggregate gross proceeds from the IPO, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $150.0 million.
About BlossomHill Therapeutics Inc..
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
- Ticker
- BLSM
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Employees
- 71
- Listed
- Aug 7, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the BlossomHill Therapeutics Inc.. IPO price?
$16.00 a share.
When did BlossomHill Therapeutics Inc.. go public?
BlossomHill Therapeutics Inc.. listed on Nasdaq on Aug 7, 2026 under the ticker BLSM.
How much did the BlossomHill Therapeutics Inc.. IPO raise?
$150M, before any underwriters' option.
How did BlossomHill Therapeutics Inc.. open on its first day?
BLSM first traded at $15.75, -1.56% from the IPO price of $16.00.
How did BLSM close on its first day?
Its last regular-session trade was $16.00, +0.00% from the IPO price of $16.00.
What was the BLSM first-day trading range?
$15.25 to $16.05 in the regular session.
How many BLSM shares traded on the first day?
1.67M shares in the regular session.
How many shares did BlossomHill Therapeutics Inc.. sell in its IPO?
9.38M shares.
How did BLSM do against the market on its first day?
BLSM rose 1.6% from its first trade to the last trade of the session. That is 1.2 points better than the market (QQQ, the Nasdaq-100 ETF).
What exchange is BLSM listed on?
BlossomHill Therapeutics Inc.. lists on Nasdaq under the ticker BLSM.
Build with Massive
Get the BLSM data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/BLSM/range/5/minute |
| Market cap | /v3/reference/tickers/BLSM |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.